-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, 2021, HUTCHMED and AstraZeneca announced that they have launched a Phase 3 clinical trial in China
Lung cancer accounts for about one-fifth of all cancer deaths
In China, Teresa was first approved for second-line treatment of EGFR-T790M mutation-positive advanced NSCLC patients in March 2017, and was approved for first-line treatment of EGFR mutation-positive advanced NSCLC patients in October 2019
And MET is a receptor tyrosine kinase
Waresa has been approved for marketing in China for the treatment of NSCLC patients with a jump mutation in MET exon 14 who have undergone systemic therapy or who have undergone disease progression or who cannot receive chemotherapy
This open-label, randomized controlled, multi-center phase 3 clinical trial will be carried out in locally advanced or metastatic NSCLC with disease progression and MET amplification after receiving EGFR inhibitor treatment.
Reference materials:
[1] HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of Certain ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy.
[2] Hutchison Medical and AstraZeneca initiated the SACHI China Phase III clinical trial of the combined therapy of ORPATHYS® (ORPATHYS®) and Teresa® (TAGRISSO®) in the treatment of specific lung cancer patients with disease progression after EGFR inhibitor treatment.
